Research.Patient.info
Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA) research hub
2 indexed studies · 0 currently recruiting
- ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.
This study is testing a new medicine, PG413, to see how it compares to an existing medicine called Eliquis. Both medicines are used to prevent strokes and treat blood clots. This early study helps us understand how PG413 works in healthy people.
Poland - ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers
This study compares two different versions of a medicine called apixaban (one is PG412, the other is Eliquis). Both help prevent blood clots. We want to see if the new version works in the body in the same way as the established one.
Poland